allsci

BMS' admilparant meets Phase III IPF endpoint at lower dose, misses at higher dose

Bristol Myers Squibb's admilparant met the Phase III ALOFT-IPF primary endpoint, showing significant FVC gains in pulmonary ...
allsci

Hansoh resubmits aumolertinib EU marketing application after data protection revocation

EU application is back under EMA review for EGFR-mutated NSCLC. Find out what this resubmission means for patients today.
allsci

J&J's oral Icotyde sustains psoriasis clearance through two years in Phase III trial

Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
allsci

NOPARK trial finds nicotinamide riboside worsens outcomes versus placebo in early Parkinson disease

A JAMA Phase III trial finds nicotinamide riboside worsens outcomes vs placebo in early Parkinson's. Read the full NOPARK ...
allsci

FDA approves Asahi Kasei's Hovilpri for treatment-refractory HSV infections

FDA approves Hovilpri (pritelivir) for herpes lesions resistant to acyclovir, valacyclovir, or famciclovir in ...
allsci

FDA approves Teva's Weltruza as first once-monthly subcutaneous LAI for schizophrenia

FDA approves Teva's Weltruza, the first once-monthly subcutaneous olanzapine LAI for adult schizophrenia. Read what it means ...
allsci

Chai Discovery lands GSK deal after successful AI binder tests

Chai Discovery and GSK announce a collaboration giving GSK access to protein folding and design AI models after wet-lab ...